NasdaqGS:REGNBiotechs
The Bull Case For Regeneron Pharmaceuticals (REGN) Could Change Following New Japanese Dupixent BP Approval
Regeneron Pharmaceuticals and Sanofi recently received Japanese Ministry of Health, Labour and Welfare approval for Dupixent as the first targeted treatment for adults with moderate-to-severe bullous pemphigoid, based on pivotal LIBERTY-BP-ADEPT phase 2/3 data showing more than four times as many patients achieved sustained disease remission versus placebo at Week 36.
This decision adds a seventh Dupixent indication in Japan, reinforcing the drug’s broad immunology footprint while addressing...